Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE
暂无分享，去创建一个
J. Cappelleri | M. Gooderham | C. Feeney | P. Biswas | H. Valdez | M. Dibonaventura | R. Rojo | C. Chu | D. Myers | M. Cameron | K. Peeples-Lamirande | Gerardo A. Encinas
[1] J. Silverberg,et al. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis , 2020, JAMA dermatology.
[2] Erika Sevetson,et al. The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association. , 2017, The Journal of investigative dermatology.